Showing 1 - 6 results of 6 for search 'J. De Bono', query time: 0.03s Refine Results
  1. 1
    Correspondence: Reply to ‘Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury’

    Correspondence: Reply to ‘Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury’ by Cheng Xue Qin, Lauren T. May, Patrick M. Sexton, Aaron J. DeBono, Jonathan B. Baell, Arthur Christopoulos, Rebecca H. Ritchie

    Published 2018-02-01
    Get full text
    Article
  2. 2
    PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL

    PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL by A. Sharp, A. Williams, S. Blagden, R. Plummer, D. Hochhauser, M. G. Krebs, S. Pacey, J. Evans, S. Whelan, S. Nandakumar, S. Rogers, K. L. Jameson, F. G. Basile, J. de Bono, H.-T. Arkenau

    Published 2022-06-01
    Get full text
    Article
  3. 3
    Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results

    Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results by J.M. Piulats, E. Yu, G. Gravis, B. Laguerre, J. Arranz, S. Oudard, P. Fong, M. Kolinsky, M. Augustin, S. Feyerabend, A.. Kam, H. Gurney, A. Tafreshi, M. Retz, W. Berry, N. Mar, H. Wu, C. Schloss, C. Poehlein, J. De Bono

    Published 2020-07-01
    Get full text
    Article
  4. 4
    KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)

    KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castrati... by G. Gravis, M. Kolinsky, L. Mourey, J.M. Piulats, S. Sridhar, E. Romano, W. Berry, H. Gurney, M. Retz, L. Appleman, M. Boegemann, J. De Bono, A. Joshua, U. Emmenegger, H. Conter, B. Laguerre, H. Wu, C. Schloss, C. Poehlein, E.Y. Yu

    Published 2020-07-01
    Get full text
    Article
  5. 5
    KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)

    KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer... by S. Feyerabend, W. Berry, P. Fong, J.M. Piulats, L. Appleman, H. Conter, N. Shore, G. Gravis, B. Laguerre, H. Gurney, M. Retz, E. Romano, L. Mourey, J. De Bono, A. Kam, U. Emmenegger, H. Wu, C. Schloss, C. Poehlein, E.Y. Yu

    Published 2020-07-01
    Get full text
    Article
  6. 6
    A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer

    A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer by C. E. Fletcher, L. Deng, F. Orafidiya, W. Yuan, M. P. G. S. Lorentzen, O. W. Cyran, A. Varela-Carver, T. A. Constantin, D. A. Leach, F. M. Dobbs, I. Figueiredo, B. Gurel, E. Parkes, D. Bogdan, R. R. Pereira, S. G. Zhao, A. Neeb, F. Issa, J. Hester, H. Kudo, Y. Liu, Y. Philippou, R. Bristow, K. Knudsen, R. J. Bryant, F. Y. Feng, S. H. Reed, I. G. Mills, J. de Bono, C. L. Bevan

    Published 2022-03-01
    Get full text
    Article

Search Tools: